Medikamentös-toxische Lebererkrankungen

Zusammenfassung

Die Inzidenz der arzneimitteltoxischen Hepatopathie liegt bei etwa 14 – 20 pro 100 000 Einwohner. Der Schlüssel zur Diagnosestellung ist eine ausführliche, akkurate Anamnese und ein Ausschluss anderer Lebererkrankungen. Die am häufigsten mit medikamentös-toxischer Hepatopathie in Verbindung stehenden Substanzgruppen sind Antibiotika, verschiedene Analgetika und nichtsteroidale Antirheumatika. In den meisten Fällen ist eine Restitutio ad integrum zu erwarten. Die wichtigsten therapeutischne Maßnahmen sind die frühzeitige Identifikation und das Absetzen der auslösenden Substanz.

Abstract

The incidence of drug induced liver injury (DILI) has been reported to be between 14 – 20 per 100 000 inhabitants. The diagnosis of DILI is based on an accurate anamnesis and exclusion of other liver diseases. Drugs most commonly involved in DILI belong to the classes of antibiotics and analgetics. The most important therapeutic issue is to identify and withdraw the toxic compound.

Schlüsselwörter

medikamentös-toxische Hepatopathien - Risikofaktoren - Rucam Score

Keywords

drug induced liver injury - risk factors - Rucam score

• Literatur

• 1 Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-455
• 2 Björnsson ES, Bergmann OM, Björnsson HK et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-1425
• 3 De Valle MB, Av Klinteberg V, Alem N et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187-1195
• 4 Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11: 477-505
• 5 Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32: 77-88
• 6 Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954
• 7 Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009; 29: 337-347
• 8 Lucena MI, Andrade RJ, Kaplowitz N et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49: 2001-2009
• 9 Lammert C, Einarsson S, Saha C et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47: 2003-2009
• 10 Lammert C, Bjornsson E, Niklasson A et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51: 615-620
• 11 Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 2002; 1: 159-172
• 12 Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury?. Gastroenterology 2004; 126: 1477-1480
• 13 Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26: 12-21
• 14 Berson A, Freneaux E, Larrey D et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug induced idiosyncratic hepatitis. J Hepatol 1994; 20: 336-342
• 15 Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145-155
• 16 Lee WM, Larrey D, Olsson R et al. Hepatic findings in longterm clinical trials of ximelagatran. Drug Saf 2005; 28: 351-370
• 17 Chalasani NP, Hayashi PH, Bonkovsky HL et al. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014; 109: 950-966
• 18 Danan Gl, Benichou C. Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330
• 19 Bohan TP, Helton E, McDonald I et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001; 56: 1405-1409
• 20 Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-1197
• 21 Lee WM, Hynan LS, Rossaro L et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage nonacetaminophen acute liver failure. Gastroenterology 2009; 137: 856-864 864 e1
• 22 Wree A, Dechêne A, Herzer K et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion 2011; 84: 54-59
• 23 Frenzel C, Teschke R. Herbal hepatotoxicity: clinical characteristics and listing compilation. Int J Mol Sci 2016; 17 (pii) E588
• 24 Andrade RJ, Lucena MI, Fernández MC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521
• 25 Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug induced liver disease. Hepatology 2005; 42: 481-489
• 26 Chalasani N, Bonkovsky HL, Fontana R et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015; 148: 1340-1352